BPC-157 — 5mg
109.99€
Retatrutide — 10mg
The first triple-receptor agonist to activate GIP, GLP-1, and glucagon pathways simultaneously, with Phase 2 data showing 24.2% body weight reduction at 48 weeks.
289.99€
Excl. btw 289.99€
- In Stock
- Evidence tier: Emerging
- Format: Lyophilized
- Purity: 99.3%
- Vial size: 10mg
Uitsluitend voor laboratoriumonderzoek. Niet voor gebruik bij mens of dier.
Over Retatrutide
Retatrutide is the world's first GLP-1/GIP/glucagon triple receptor agonist to enter advanced clinical study. By engaging three distinct metabolic pathways simultaneously, it has generated unprecedented body composition data in published trials. It represents the next evolution beyond dual-agonist peptides like tirzepatide.
Retatrutide is the world's first GLP-1/GIP/glucagon triple receptor agonist to enter advanced clinical study. By engaging three distinct metabolic pathways simultaneously, it has generated unprecedented body composition data in published trials. It represents the next evolution beyond dual-agonist peptides like tirzepatide.
Retatrutide (LY3437943) is a single polypeptide conjugated to a fatty diacid moiety that activates GIP, GLP-1, and glucagon receptors. The triple agonism provides complementary metabolic benefits: GLP-1 reduces appetite and slows gastric emptying, GIP enhances insulin sensitivity and may promote fat storage efficiency, and glucagon receptor activation increases hepatic fat oxidation, energy expenditure, and thermogenesis. The glucagon component also significantly reduces hepatic steatosis, with Phase 2 data showing near-complete resolution of MASLD/MASH in some participants.
Duidelijkheid van het mechanisme: Well-characterized triple GIP/GLP-1/glucagon agonism
Tags
Belangrijkste punten
-
Onderzoeksscore 7/10
Phase 2 completed, Phase 3 (TRIUMPH) ongoing gepubliceerde studies in de dataset
-
Bewijsniveau: Emerging
Emerging — Phase 2 complete with remarkable results (24.2% weight loss). Phase 3 (TRIUMPH program by Eli Lilly) underway. Not yet FDA-approved. Very promising but limited to one major Phase 2 trial published.
-
Gegevens bij mensen
Phase 2 RCT with ~300 participants (NEJM published)
Opslag en hantering
Gevriesdroogd poeder: Room temp or refrigerated
Na reconstitutie: Refrigerate, use within 30 days
Reconstitutiestappen uit de dataset
- Clean. Remove flip-top cap and swab rubber stopper with alcohol.
- Draw water. Draw 2mL of bacteriostatic water into syringe.
- Inject water. Insert needle through stopper and slowly inject water down the side of the vial. Do not spray directly onto powder.
- Dissolve. Gently swirl (do not shake) until fully dissolved. Solution should be clear.
- Label. Label vial with date and concentration (5mg/mL). Refrigerate immediately.
- Dose. For 1mg dose: draw 0.2mL (20 units). For 2mg dose: draw 0.4mL (40 units). Inject subcutaneously once weekly.
Veiligheid en beperkingen
Onderzocht voor: Weight loss, Metabolic syndrome, Prediabetes reversal, NAFLD/MASH, Body recomposition
Gemelde aanvang: 2-4 weeks for appetite effects; 8-12 weeks for significant weight loss
Gemelde duur: Ongoing; dose escalation monthly from 0.5mg to 12mg
Meldingen uit de community: Nausea more common than tirzepatide at higher doses (25%+). GI side effects dose-dependent. Limited community data due to early-stage availability. Clinical trial participants report dramatic weight loss and tolerable side effects.
For research and educational use only. Source values are reproduced from the current PeptidesEuro content dataset and are not medical advice.
Kwaliteit en specificaties
Product details
- Productcode
- L-RETA-10
- Beschikbaarheid
- In Stock
- Evidence tier
- Emerging
- Format
- Lyophilized
- Purity
- 99.3%
- Vial size
- 10mg
Reconstitutiereferentie
- Bacteriostatisch water
- 2 mL
- Concentratie
- 5mg/mL when reconstituted with 2mL. 1mg dose = 0.2mL (20 units on insulin syringe).
- Spuit
- 29-31G insulin syringe
Onderzoeksparameters
- Standaardhoeveelheid
- 1000 µg
- Alternatieve hoeveelheid
- 4000 µg
- Flacon
- 10 mg
- Schatting uit de dataset
- 1 vial lasts 10 weeks at 1mg/week
Laboratoriumrapport
- Laboratorium
- Janoshik Analytical
- Testdatum
- 2026-03-01
- Document
- Pdf niet bijgevoegd
Bekijk de wetenschap
-
Lees de studie: Triple hormone receptor agonist retatrutide for MASLD (opent in een nieuw tabblad)
Triple hormone receptor agonist retatrutide for MASLD
Significant liver fat reduction; potential MASH resolution in Phase 2 participants
-
Lees de studie: Triple-Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2 Trial (opent in een nieuw tabblad)
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2 Trial
Up to 24.2% weight loss at 48 weeks; 72% of prediabetic participants reverted to normoglycemia
-
Lees de studie: Retatrutide — A Game Changer in Obesity Pharmacotherapy (opent in een nieuw tabblad)
Retatrutide — A Game Changer in Obesity Pharmacotherapy
Potent activation of all three receptors (GIP/GLP-1/glucagon); significant weight reduction and metabolic improvements
Studies worden ter referentie vermeld. De meeste zijn uitgevoerd in dier- of celmodellen; de resultaten tonen geen veiligheid of werking bij mensen aan.
Verder lezen
Community evidence
- Source window English Reddit Updated 13 Aug 2026 · 2-year window
- Coverage confidence Low Confidence in the available community sample
- Distribution Pending Not enough data for a distribution.
Selected reports
-
1 year agor/Testosterone · Post
my face most notably returned to pre-trt levels of water retention literally in about 2 weeks
-
3 months agor/RetatrutideWomen · Post
My dosing was: 500 mcg for 5 weeks 750 mcg for 5 weeks 1 mg for 1 week I stopped cold turkey 3 weeks ago with no tapering.Towards the end of the cycle and for a while after stopping, I felt really rough. … Hey everyone,Wanted to share my experience with Retatrutide (reta) in cas…
Based on 2 qualifying reports from 2 threads. 39 candidates excluded as duplicates, promotion, deleted content, or lacking concrete personal experience. Reddit self-reports are not medical evidence or proof of causation.
Vragen over Retatrutide
Vragen en antwoorden die bij dit product zijn vastgelegd.
Not yet. Phase 2 is complete with remarkable results. Phase 3 (TRIUMPH program by Eli Lilly) is currently underway. It is the most advanced triple agonist candidate in development.
Phase 2 data published in Nature Medicine showed significant liver fat reduction, with near-complete MASLD/MASH resolution in some participants. The glucagon receptor component specifically drives hepatic fat oxidation — an effect unique to triple agonists.
Retatrutide is a triple agonist (GIP + GLP-1 + glucagon) while tirzepatide is a dual agonist (GIP + GLP-1). The added glucagon receptor activation drives hepatic fat oxidation and energy expenditure. Phase 2 data showed up to 24.2% weight loss vs tirzepatide's 22.5% in separate trials.
Beoordelingen
Er zijn nog geen beoordelingen voor dit product.
Gerelateerde producten
-
-
MOTS-c — 10mg
189.99€
-
Tirzepatide — 10mg
189.99€
-
Tesamorelin — 10mg
279.99€
Zo werkt bestellen
Productgegevens, bronnen en je bestelling blijven met elkaar verbonden.
-
Kies de verbinding
Kies een verbinding en flaconmaat in de catalogus.
-
Bekijk de productinformatie
Open de productdetails en het onderliggende onderzoek.
-
Bewaar de bronnen
Bewaar de bronvermeldingen voor je administratie.
Waarom bestellen bij PeptidesEuro
Verbindingsprofielen
Structuur, beschikbare hoeveelheden en hanteringsnotities op één plek.
Studiebronnen
Productpagina's verwijzen naar de studies achter elke verbinding.
Eén bestelhistorie
Bestellingen en hun details blijven in je account.
Duidelijke productgegevens
Prijs, voorraadstatus en btw staan bij elk product.
PeptidesEuro is a research materials supplier operated by Pepticore LLC. We provide high-purity peptides and research compounds for in-vitro laboratory and scientific research purposes. All products are sold strictly for research use only and are not intended for human or animal consumption.
No. All products sold through meimx.com are intended strictly for in-vitro laboratory and scientific research purposes only. They are not intended for human or animal consumption, injection, ingestion, inhalation, or any form of administration to living organisms. By purchasing from PeptidesEuro, you acknowledge and agree to these terms as outlined in our Terms of Service.
No. Our products have not been evaluated, approved, or authorized by the U.S. Food and Drug Administration (FDA) or any other regulatory body. They are not intended to diagnose, treat, cure, mitigate, or prevent any disease or medical condition. PeptidesEuro is not a compounding pharmacy or outsourcing facility as defined under Sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act.
No. PeptidesEuro does not provide medical advice, treatment recommendations, or dosing instructions. Any information on our website, including product descriptions and referenced research, is provided for educational and informational purposes only. If you have medical questions, please consult a licensed healthcare provider.
Research Use Only means that our products are sold exclusively as reference standards and research materials for use in laboratory and scientific research settings. Purchasers agree to use all products solely for legitimate research purposes in compliance with all applicable laws and regulations.
Klaar om Retatrutide te bestellen?
Blader door de catalogus of beantwoord één vraag in de productzoeker.